N-acetylcysteine for non-paracetamol drug-induced liver injury: A systematic review

British Journal of Clinical Pharmacology

Volumn 81, Issue 6, 2016, Pages 1021-1029

  Chughlay, Mohamed Farouk ^a   Kramer, Nicole ^a   Spearman, C Wendy ^a   Werfalli, Mahmoud ^a   Cohen, Karen ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

drug induced; hepatitis; liver failure; N acetylcysteine; non acetaminophen; non paracetamol

Indexed keywords

ACETYLCYSTEINE; PLACEBO; SCAVENGER;

BLOOD CLOTTING DISORDER; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECT; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; LENGTH OF STAY; LIVER GRAFT; META ANALYSIS; MORTALITY; NON PARACETAMOL DRUG INDUCED LIVER INJURY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TOXIC HEPATITIS; TREATMENT OUTCOME; CHEMICAL AND DRUG INDUCED LIVER INJURY;

ACETYLCYSTEINE; CHEMICAL AND DRUG INDUCED LIVER INJURY; FREE RADICAL SCAVENGERS; HUMANS;

EID: 84959523803     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12880     Document Type: Review

References (37)

1. Davern TJ,. Drug-induced liver disease. Clin Liver Dis 2012; 16: 231-45.
2. Leise MD, Poterucha JJ, Talwalkar JA,. Drug-induced liver injury. Mayo Clin Proc 2014; 89: 95-106.
3. Navarro VJ, Senior JR,. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-9.
4. Mouton JP, Mehta U, Parrish AG, Wilson DP, Stewart A, Njuguna CW, Kramer N, Maartens G, Blockman M, Cohen K,. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. Br J Clin Pharmacol 2015; 80: 818-26.
5. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S,. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.
6. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P,. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.
7. Lheureux PER, Hantson P,. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009; 47: 101-11.
8. Brok J, Buckley N, Gluud C,. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2006 Apr 19; CD003328.
9. Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT,. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2: 1097-100.
10. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ, Murray NG, McCashland T, Reisch JS, Robuck PR,. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137: 856-64.
11. Mumtaz K, Azam Z, Hamid S, Abid S, Memon S, Ali Shah H, Jafri W,. Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation. Hepatol Int 2009; 3: 563-70.
12. Kortsalioudaki C, Taylor RM, Cheeseman P, Bansal S, Mieli-Vergani G, Dhawan A,. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl 2008; 14: 25-30.
13. Montanini S, Sinardi D, Praticò C, Sinardi A,. Use of acetylcysteine as the life-saving antidote in amanita phalloides (death cap) poisoning. Case report on 11 patients. Arzneimittelforschung 1999; 49: 1044-7.
14. Nair GB, Ilowite JS,. Pharmacologic agents for mucus clearance in bronchiectasis. Clin Chest Med 2012; 33: 363-70.
15. Fishbane S,. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol 2004; 15: 251-60.
16. Yalçin E, Altin F, Cinhüseyinoglue F, Arslan MO,. N-acetylcysteine in chronic blepharitis. Cornea 2002; 21: 164-8.
17. Akyol-Salman I, Azizi S, Mumcu U, Baykal O,. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther 2010; 26: 329-33.
18. Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH,. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991; 20: 1058-63.
19. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R,. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324: 1852-7.
20. Suk KT, Kim DJ,. Drug-induced liver injury: present and future. Clin Mol Hepatol 2012; 18: 249-57.
21. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH,. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319: 1557-62.
22. Harrison PM, Keays R, Bray GP, Alexander GJM, Williams R,. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 335: 1572-3.
23. Harrison P, Wendon J, Williams R,. Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure. Hepatology 1996; 23: 1067-72.
24. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, Williams R,. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991; 303: 1026-9.
25. Chughlay MF, Kramer N, Werfalli M, Spearman W, Engel ME, Cohen K,. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol. Syst Rev 2015; 4: 84.
26. Danan G, Benichou C,. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.
27. Benichou C, Danan G, Flahault A,. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6.
28. Maria VA, Victorino RM,. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-9.
29. Agarwal VK, McHutchison JG, Hoofnagle JH,. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-70.
30. National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. May 29, 2009 NIH publication # 09-7473
31. Higgins J, Green S,. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011].
32. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
33. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
34. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT02182167, A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis (NAC in TB DIH); 2014 Jun 18 [1 screen]. Available at https://clinicaltrials.gov/ct2/show/NCT02182167?term=N-acetylcysteine+hepatitis&rank=5 (last accessed 20 Jun 2015).
35. Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR, Velayati AA,. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010; 22: 1235-8.
36. Squires RH, Dhawan A, Alonso E, Narkewicz MR, Shneider BL, Rodriguez-Baez N, Olio DD, Karpen S, Bucuvalas J, Lobritto S, Rand E, Rosenthal P, Horslen S, Ng V, Subbarao G, Kerkar N, Rudnick D, Lopez MJ, Schwarz K, Romero R, Elisofon S, Doo E, Robuck PR, Lawlor S, Belle SH,. Intravenous N-acetylcysteine in pediatric patients with non-acetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology 2013; 57: 1542-9.
37. Jong E, Conradie F, Berhanu R, Black A, John M-A, Meintjes G, Menezes C,. Consensus statement: management of drug-induced liver injury in HIV-positive patients treated for TB. South Afr J HIV Med 2013; 14: 113-9.